-
Mashup Score: 8
In high-risk HR+/HER2- early breast cancer (EBC), nanoparticle albumin-bound (nab)-paclitaxel showed promising efficacy vs solvent-based (sb)-paclitaxel in neoadjuvant trials, however, optimal patient and therapy selection remains a topic of ongoing research. Here, we investigate the potential of Oncotype DX Recurrence Score (RS) and endocrine therapy (ET) response (low post-endocrine Ki67) for…
Source: Annals of OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6
Early detection of cancer offers the opportunity to identify candidates when curative treatments are achievable. The THUNDER study (THe UNintrusive Detection of EaRly-stage cancers, NCT04820868) aimed to evaluate the performance of enhanced linear-splinter amplification sequencing, a previously described cell-free DNA (cfDNA) methylation-based technology, in the early detection and localization…
Source: Annals of OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
cfDNA 🩸🧬methylation for early cancer detection: results of the THUNDER study (THe UNintrusive Detection of EaRly-stage cancers, NCT04820868) in colorectal, esophageal, liver, lung, ovarian, and pancreatic cancers are published in Annals of Oncology https://t.co/X7aFnJW26M
-
-
Mashup Score: 3Next Generation Radiotheranostics Promoting Precision Medicine - 1 year(s) ago
Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-Dotatate for neuroendocrine tumors, and 177Lu-PSMA for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future…
Source: Annals of OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Combining diagnostics with therapeutics: this review in Annals of Oncology describes the basics of radiotheranostics ☢️ , current use, challenges and perspectives 👇 https://t.co/Tv9R9xTaOV https://t.co/GOHfZNNPCO
-
-
Mashup Score: 0
The phase I/II FIGHT-101 study (NCT02393248) evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of pemigatinib, a potent and selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor, as monotherapy or in combination therapy, for refractory advanced malignancies, with and without fibroblast growth factor (FGF) and receptor (FGFR) gene alterations.
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies - Annals of Oncology https://t.co/L1YWM0Latn
-
-
Mashup Score: 0
The following ESMO Clinical Practice Guideline has been recently updated with new treatment recommendations: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.1
Source: Annals of OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🆕In Annals of Oncology, updates for the @myESMO Clinical Practice Guideline for prostate cancer: recommendations considering treatment intensification and use of novel systemic agents https://t.co/Aa1xU3uaiw
-
-
Mashup Score: 23Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - 1 year(s) ago
Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2022.10.001).1 The aim of this European Society for Medical Oncology (ESMO) Clinical Practice…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up @Annals_Oncology @myESMO #immunotherapy https://t.co/cuhpqkbxQI
-
-
Mashup Score: 2
Carboplatin-paclitaxel (CP) is standard of care (SOC) for first-line treatment of primary A/R EC; median OS is <3 yrs. Use of anti–PD-1s with chemo has improved outcomes in multiple tumour types. RUBY (NCT03981796) evaluated the efficacy and safety of the anti–PD-1 dostarlimab (D)+CP in A/R EC compared with CP alone.
Source: Annals of OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The abstract of the RUBY phase III RCT investigating anti–PD-1 moAb dostarlimab in combination with 1st-line chemotherapy in metastatic endometrial cancer and presented during the March 28th 2023 #ESMOVirtualPlenary is available in Annals of Oncology: https://t.co/ssjukherQE
-
-
Mashup Score: 0Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study☆ - 1 year(s) ago
Genomic analysis of circulating tumor DNA (ctDNA) is increasingly incorporated into the clinical management of patients with advanced cancer. Beyond tumor profiling, ctDNA analysis also can enable calculation of circulating tumor fraction (TF), which has previously been found to be prognostic. While most prognostic models in metastatic cancer are tumor type specific and require significant…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@Dr_R_Kurzrock Agree! A paradox I've noticed too - better outcomes if tumor positive / liquid NEG (ie discordant, no ctDNA shed). Would be good to look at ctDNA tumor fraction in this cohort, which we @StoverLab have found consistently prognostic across cancer types: https://t.co/JJyM5AoHLU
-
-
Mashup Score: 1
The following ESMO Clinical Practice Guideline has been recently updated with new treatment recommendations: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.1
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @mjuanfi81: If you only have time to check “one thing”, here it is what you should review carefully. https://t.co/XGocNFeCOG
-
-
Mashup Score: 9Cancer: slaying the nine-headed Hydra - 1 year(s) ago
Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Cancer: slaying the nine-headed Hydra @Annals_Oncology @esmo @jacobadashek @Dr_R_Kurzrock @BenWestphalen @ANaingMD @OncoAlert https://t.co/5ybu1LXtco
-
The the WSG-ADAPT trial investigated weekly nab-paclitaxel vs paclitaxel 175 mg/m2 q2w as neoadjuvant therapy including EC) for high-risk HR+/HER2- early breast cancer. Oncotype DX and endocrine therapy response were used for patient screening 👇https://t.co/09rfwmuq6F #bcsm